Economical evaluation of the treatment of invasive aspergillosis in pediatric oncology patients. Santiago. Chile

Invasive aspergillosis (IA) is a serious opportunistic infection in immunocompromised patients. Transplant recipients and patients with cancer represent the highest risk group. The antifungal treatment involves prolonged hospitalization and high economic resources. to estimate costs represented by I...

Full description

Saved in:
Bibliographic Details
Published in:Revista chilena de infectología 2010-08, Vol.27 (4), p.302-307
Main Authors: Moreno, Claudia, del Valle, Gladys, Coria, Paulina
Format: Article
Language:Spanish
Subjects:
Adolescent
Antifungal Agents - economics
Antifungal Agents - therapeutic use
Antigens, Fungal - economics
Antigens, Fungal - therapeutic use
Aspergillosis - complications
Aspergillosis - drug therapy
Aspergillosis - economics
Case-Control Studies
Child
Chile
Cross Infection - economics
Female
Health Care Costs - statistics & numerical data
Humans
Immunocompromised Host
Male
Mannans - blood
Mannans - economics
Neoplasms - complications
Opportunistic Infections - complications
Opportunistic Infections - drug therapy
Opportunistic Infections - economics
Retrospective Studies
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Invasive aspergillosis (IA) is a serious opportunistic infection in immunocompromised patients. Transplant recipients and patients with cancer represent the highest risk group. The antifungal treatment involves prolonged hospitalization and high economic resources. to estimate costs represented by IA as an intercurrent complication of oncologic treatment. Retrospective case-control study. Estimation of the cost of treatment in pediatric oncologic patients with IA in the Hospital Luis Calvo Mackenna during the years 2007-2008 was done. A control for each case of IA paired by sex, age, number of diagnosis and clinical department was selected. There were 13 patients during the observation period. The attributable cost of treatment of aspergillosis was US $23,600 and the cost for each indicator was: hospital days US $16,500; antifungal therapy US $7,000; and serum galactomannan US $100. In this study, the cost of treating IA is mainly due to hospitalization and antifungal medications. Three patients acquired IA in spite of staying in a protected environment.
ISSN:0716-1018